104 LiPCaiJYuanSLiYShiHLiangCet al
The $1.8 billion projection for 2026 requires 4.5x year-over-year growth in a market where regulatory scrutiny is increasing, competition is intensifying, and the FDA compounding loophole that makes the entire business model possible could close at any time
Foundayo is a GLP-1 receptor agonist, which means it activates the same receptors as a hormone found naturally in your body called GLP-1, mimicking its effects in your body
Eli Lillys Phase 3 TRIUMPH-4 trial (December 2025) reported that participants taking 12mg of Retatrutide over 68 weeks lost an average of 28.7% of their body weight, the highest result ever reported at that stage for any obesity-related compound
Evidence from Related Medications: Research on other GLP-1 drugs shows mixed effects
GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists) are a class of prescription medications originally developed for type 2 diabetes that have shown remarkable effectiveness for weight management